Sterling Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Sterling Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-602	Closed	-$13K	–	3214
2025 Q4	$13K	Buy	602 +386	+179%	+$7.49K	﹤0.01%	2477
2025 Q3	$3.3K	Buy	216 +1	+0.5%	+$13	﹤0.01%	2893
2025 Q2	$1.9K	Buy	215 +120	+126%	+$1.05K	﹤0.01%	2932
2025 Q1	$744	Hold	95	–	–	﹤0.01%	2897
2024 Q4	$998	Hold	95	–	–	﹤0.01%	2942
2024 Q3	$1.25K	Buy	+95	New	+$1.45K	﹤0.01%	2418
2015 Q1	–	Sell	-18,000	Closed	-$308K	–	876
2014 Q4	$308K	Buy	+18,000	New	+$257K	﹤0.01%	836

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Sterling Capital Management's AVDL Position: Q1 2026 in Review

Sterling Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 602 shares — an estimated $13K sold.

Sterling Capital Management first reported a position in AVDL in Q4 2014 and held it in 7 quarters. The position peaked at $308K in Q4 2014. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Sterling Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Sterling Capital Management sold 602 Avadel Pharmaceuticals shares in Q1 2026, an estimated $13K.
Sterling Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 7 quarters.
Sterling Capital Management's Avadel Pharmaceuticals position peaked at $308K in Q4 2014.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.